Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have received an average rating of “Buy” from the sixteen brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $26.90.
Several research analysts have recently commented on the company. Raymond James Financial assumed coverage on Voyager Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $35.00 price target for the company. Stifel Nicolaus reiterated a “buy” rating and issued a $31.00 price objective (up from $20.00) on shares of Voyager Therapeutics in a research note on Monday, October 23rd. Chardan Capital reiterated a “hold” rating and issued a $17.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Cowen reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, Wedbush reiterated a “positive” rating and issued a $31.00 price objective (down from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st.
In other news, insider Bernard Ravina sold 3,630 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total value of $59,532.00. Following the sale, the insider now directly owns 7,353 shares in the company, valued at $120,589.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 14,610 shares of company stock worth $207,158. Insiders own 8.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in VYGR. Russell Investments Group Ltd. raised its stake in Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Voyager Therapeutics in the second quarter valued at $143,000. Rhumbline Advisers raised its stake in Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after buying an additional 4,144 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after buying an additional 1,399 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Voyager Therapeutics by 24.7% in the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after buying an additional 5,081 shares in the last quarter. Institutional investors and hedge funds own 35.97% of the company’s stock.
Voyager Therapeutics (NASDAQ VYGR) traded up $0.11 on Tuesday, hitting $18.38. The stock had a trading volume of 212,557 shares, compared to its average volume of 387,631. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99. The stock has a market capitalization of $495.33 and a price-to-earnings ratio of -6.47.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.17). Voyager Therapeutics had a negative return on equity of 65.50% and a negative net margin of 1,195.63%. equities research analysts expect that Voyager Therapeutics will post -2.99 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics Inc (VYGR) Receives Consensus Recommendation of “Buy” from Analysts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/voyager-therapeutics-inc-vygr-receives-consensus-recommendation-of-buy-from-analysts.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.